RecruitingSolid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma
A Study of VET3-TGI in Patients With Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
Sponsor: KaliVir Immunotherapeutics
Where it's recruiting
California
Los Angeles · Orange
Florida
Miami
Indiana
Indianapolis
Pennsylvania
Pittsburgh
Texas
Dallas · Houston
Source: ClinicalTrials.gov · NCT06444815 · last updated 2026-04-07